Pfizer has appointed Andrew Baum, head of global health and managing director of equity research at Citi, as its new head of strategy and innovation.
Baum, a physician, has been with Citi (C) since 2011. Before joining Citi, he covered European pharmaceuticals. firm at morgan stanley (Ms) for 14 years.
He will report to CEO Albert Bourla.
In his new role, Baum will help manage the drugmaker's long-term strategic plan. “He will also be responsible for our portfolio analysis and prioritization functions, business development activities, strengthening our partnerships with the biotechnology ecosystem, and commercial evaluation of our research pipeline,” according to a press release.
Baum will also chair Pfizer (New York Stock Exchange: BFI) The portfolio management team, which is responsible for allocating capital into the company's R&D pipeline.